Status:
TERMINATED
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.
Eligibility Criteria
Inclusion
- This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia) and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia)
- Patients must have adequate organ function
- Patients must have documented T315I mutation
Exclusion
- Patients within 3 months of allogeneic bone marrow transplant or not fully recovered from previous anti-leukemia therapy
- Patients with uncontrolled congestive heart failure
- Patients with active or uncontrolled infection or active Hepatitis B or C
- Patients with known HIV positivity or AIDS related illness
- Patients with currently active second malignancy, other than non-melanoma skin cancer.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00405054
Start Date
December 1 2006
End Date
June 1 2009
Last Update
January 26 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.